Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 28 1 50 versus WOLFINA.
NORLESTRIN 28 1/50 vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Not specified in available data; likely unapproved or investigational drug.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive